Galapagos NV
GLPG
#4563
Rank
โ‚น189.74 B
Marketcap
โ‚น2,838
Share price
-0.57%
Change (1 day)
24.35%
Change (1 year)

Revenue for Galapagos NV (GLPG)

Revenue in 2025 (TTM): โ‚น27.68 Billion

According to Galapagos NV's latest financial reports the company's current revenue (TTM ) is โ‚น28.76 Billion. In 2024 the company made a revenue of โ‚น25.40 Billion an increase over the revenue in the year 2023 that were of โ‚น10.25 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Galapagos NV from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น27.68 B8.97%
2024 โ‚น25.40 B147.77%
2023 โ‚น10.25 B-76.64%
2022 โ‚น43.89 B4.8%
2021 โ‚น41.88 B5.34%
2020 โ‚น39.76 B-39.94%
2019 โ‚น66.20 B181.28%
2018 โ‚น23.53 B152.86%
2017 โ‚น9.30 B-1.85%
2016 โ‚น9.48 B229.26%
2015 โ‚น2.88 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
AstraZeneca
AZN
โ‚น5.221 T 18,056.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Johnson & Johnson
JNJ
โ‚น8.278 T 28,683.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น4.269 T 14,744.74%๐Ÿ‡ซ๐Ÿ‡ท France
AbbVie
ABBV
โ‚น5.358 T 18,530.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Fortress Biotech
FBIO
โ‚น5.32 B-81.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
โ‚น3.938 T 13,594.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น1.507 T 5,140.08%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
GlaxoSmithKline
GSK
โ‚น3.804 T 13,129.14%๐Ÿ‡ฌ๐Ÿ‡ง UK
Merck
MRK
โ‚น5.770 T 19,964.19%๐Ÿ‡บ๐Ÿ‡ธ USA